Number needed to treat: difference between revisions
Diff·revision 9 → 10·23:44, 17 Feb 2025
Difference between revision 9 and revision 10 of Number needed to treat. 8 lines changed; the page grew by 390 bytes.
| Revision 9 — 11:19, 19 Jan 2025 DataTableDunja (talk) rm the cross-trial comparison; the populations are not comparable 3,241 bytes +34 | Revision 10 — 23:44, 17 Feb 2025 FlowTrialFraser (talk) cite the trial publication rather than the sponsor press release 3,631 bytes +390 | ||
|---|---|---|---|
| 28 | In SELECT, discontinuation for adverse events occurred in 16.6% on semaglutide against 8.2% on placebo — an absolute difference of 8.4 percentage points, giving a number needed to harm of about 12 for that outcome over the same period.{{r|lincoff2023}} | 28 | In SELECT, discontinuation for adverse events occurred in 16.6% on semaglutide against 8.2% on placebo — an absolute difference of 8.4 percentage points, giving a number needed to harm of about 12 for that outcome over the same period.{{r|lincoff2023}} |
| 29 | 29 | ||
| + | 30 | Presenting the two side by side is more informative than either alone, and it makes explicit that the outcomes being traded are of different kinds: a cardiovascular event and a discontinuation are not commensurable, and no arithmetic makes them so.{{r|altman1998}} | |
| + | 31 | ||
| 30 | == References == | 32 | == References == |
| 31 | {{reflist}} | 33 | {{reflist}} |
| ⋮ | ⋮ | ||
| 33 | <ref name="altman1998">Altman DG. "Confidence intervals for the number needed to treat." ''BMJ'' 317(7168):1309–1312 (1998). PMID 9804726.</ref> | 35 | <ref name="altman1998">Altman DG. "Confidence intervals for the number needed to treat." ''BMJ'' 317(7168):1309–1312 (1998). PMID 9804726.</ref> |
| 34 | <ref name="lincoff2023">Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. "Semaglutide and cardiovascular outcomes in obesity without diabetes." ''New England Journal of Medicine'' 389(24):2221–2232 (2023). PMID 37952131.</ref> | 36 | <ref name="lincoff2023">Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. "Semaglutide and cardiovascular outcomes in obesity without diabetes." ''New England Journal of Medicine'' 389(24):2221–2232 (2023). PMID 37952131.</ref> |
| + | 37 | ||
| + | 38 | == See also == | |
| + | 39 | * [[Placebo-adjusted effect]] | |
| + | 40 | * [[Intention-to-treat analysis]] | |
| + | 41 | * [[SELECT trial]] | |
| + | 42 | * [[Surrogate endpoint]] | |
| 35 | 43 | ||
| 36 | {{DEFAULTSORT:Number needed to treat}} | 44 | {{DEFAULTSORT:Number needed to treat}} |